MARKET

SRPT

SRPT

Sarepta
NASDAQ

Real-time Quotes | Nasdaq Last Sale

161.98
-6.83
-4.05%
After Hours: 162.00 +0.02 +0.01% 16:47 07/13 EDT
OPEN
169.61
PREV CLOSE
168.81
HIGH
170.70
LOW
160.94
VOLUME
765.04K
TURNOVER
--
52 WEEK HIGH
172.70
52 WEEK LOW
72.05
MARKET CAP
12.63B
P/E (TTM)
-18.3439
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 24 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SRPT stock price target is 194.55 with a high estimate of 260.00 and a low estimate of 150.00.

EPS

SRPT News

More
Did Hedge Funds Make The Right Call On Sarepta Therapeutics Inc (SRPT) ?
Insider Monkey · 2d ago
The Daily Biotech Pulse: Novartis Settles Lawsuit For $678M, Sarepta In-Licenses Gene Therapy Pre-Treatment, Unity Biotech Outlines Second-Half Catalysts
Benzinga · 07/02 13:21
The Daily Biotech Pulse: Novartis Settles Lawsuit For $678M, Sarepta In-Licenses Gene Therapy Pre-Treatment, Unity Biotech Outlines Second-Half Catalysts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1)
Benzinga · 07/02 12:21
Sarepta Therapeutics Signs Agreement with Hansa Biopharma for Imlifidase
GlobeNewswire · 07/02 12:00
Sarepta Therapeutics inks deal for imlifidase for use in muscular dystrophies
Seeking Alpha - Article · 07/02 11:32
Sarepta Therapeutics Reports Exclusive Global License Deal With Hansa Biopharma For Development, Promotion Of Imlifidase; Hansa To Receive $10M Upfront Payment, Will Be Eligible For $397.5M In Milestones
Benzinga · 07/02 11:01
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 06/30 23:15
Sarepta Therapeutics Announces Retirement of Sandy Mahatme, Chief Financial Officer and Chief Business Officer
GlobeNewswire · 06/30 13:30

Industry

Biotechnology & Medical Research
-1.52%
Pharmaceuticals & Medical Research
+0.01%

Hot Stocks

Symbol
Price
%Change

About SRPT

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.
More

Webull offers kinds of Sarepta Therapeutics Inc stock information, including NASDAQ:SRPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRPT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SRPT stock methods without spending real money on the virtual paper trading platform.